000			03886nam a22003495i 4500
999			_c399211 _d399211
001			399211
003			ES-MaUEC
005			20240323135041.0
006			a|||| o|||| 00| 0
007			cr nn 008mamaa
008			230711s2023 sz | o |||| 0|eng d
020			_a9783031297502
024	7		_a10.1007/978-3-031-29750-2 _2doi
040			_aES-MaUEC _bspa _cES-MaUEC _dES-MaUEC
050		4	_aRC280 .M4 _b2023 EB
245	0	0	_aBiological and Clinical Landscape of Meningiomas _cedited by Gelareh Zadeh, Roland Goldbrunner, Boris Krischek, Farshad Nassiri
250			_a1st ed. 2023
264		1	_aCham _bSpringer International Publishing _c2023
300			_a1 recurso en línea
336			_atexto _btxt _2rdacontent
337			_aelectrónico _bc _2rdamedia
338			_arecurso electrónico _bcr _2rdacarrier
490	0		_aAdvances in Experimental Medicine and Biology _x2214-8019 _v1416
505	0		_aChapter 1. Introduction and History of Meningiomas -- Chapter 2. Clinical Presentation and Prognosis -- Chapter 3. Imaging Characteristics of Meningiomas -- Chapter 4. Histopathology of Meningiomas -- Chapter 5. Skull Base Meningiomas -- Chapter 6. Spinal Meningiomas -- Chapter 7. Surgical Therapies -- Chapter 8. Radiation Therapies -- Chapter 9. Illustrative Cases -- Chapter 10. Advances in CNS Tumor Classification -- Chapter 11. Genomic Landscape -- Chapter 12. Radiation-Induced Meningiomas -- Chapter 13. Meningioma Predisposing Syndromes -- Chapter 14. Epigentic Landscape -- Chapter 15. Immune Profile -- Chapter 16. PDX Models/Mouse Models/Cell Lines -- Chapter 17. Novel Medical Therapies -- Chapter 18. Quality of Life in Menigioma Patients -- Chapter 19. Illustrative Cases: Revisited with Adjuvant Molecular Data -- Chapter 20. Future Directions in Management.
520			_a"Meningiomas are tumors that originate from the arachnoidal cap cells of the leptomeninges. With an incidence rate of 8.36 per 100, 000 population, they are the most common primary central nervous system (CNS) tumors, accounting for a third of all cases. The World Health Organization (WHO) classification has traditionally categorized meningiomas into 15 different histopathological subtypes and three clinical grades. Tumors are classified as WHO grades 1, 2 or 3 based largely on histopathological features such as mitotic activity, presence of brain invasion, and other atypical features. However, there is increasing recognition of the limitations of histopathology including but not limited to: confounding factors such as sampling bias in a heterogeneous tumor, and technical factors related to the experience of the grading pathologist. Even with careful histologic grading, there remains significant variability in recurrence rates within each tumor grade. As more studies have uncovered the molecular features of meningiomas, novel biological alterations have helped refine classification schemes that more accurately reflect patient outcomes. This book reviews the current state of knowledge on the genomic and epigenomic landscape of meningiomas in order to identify the roles of genomic aberrations on diagnosis, prognosis, and treatment of meningiomas in addition to mainstays of surgical management, radiation therapy, and potential novel chemotherapies. Written by a team of world-renowned experts in neurosurgery, neuropathology, radiology, and radiation-oncology, this book is the definitive resource on meningioma management and investigation for both clinicians and scientists alike.".
988			_aSpringer_BiomedLife_2023
650		7	_2embne _9689897 _aMeningioma
650		7	_2embne _9214753 _aCerebro _xTumores
856	4	0	_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://doi.org/10.1007/978-3-031-29750-2 _zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
942			_2lcc _cLE
998			_b03/2024 _dz _eIG _zSI